The findings from this single-arm, phase II trial suggest that palbociclib has activity in advanced sarcomas other than WD/DD-LPS selected by RNA expression of CDK4 and CDKN2A, showing a promising median PFS and OS in a heavily pretreated population. The gene discussed is CDKN2A; the disease is sarcoma.